This page shows the latest Tecentriq news and features for those working in and with pharma, biotech and healthcare.
Subcutaneous administration of Roche’s Tecentriq could cut treatment time by up to 75%. ... NHS England will be the first health system in the world to roll out the subcutaneous formulation of Tecentriq (atezolizumab) to eligible patients, following a
The Tecentriq investigational combination reduced the risk of cancer returning by 28%, compared with active surveillance, at a median follow-up of 17.4 months. ... Safety for both Tecentriq and Avastin was reportedly consistent with the known safety
Tecentriq in combination with Avastin significantly improved recurrence-free survival. Genentech – a member of the Roche group – has announced that its phase 3 study of Tecentriq (atezolizumab) combination mets its primary ... Safety for both
Roche’s Tecentriq is a cancer immunotherapy that has the potential to be used in combination with other immunotherapies, targeted medicines and various chemotherapies across a broad range of cancers. ... cancer (NSCLC) for whom prior platinum therapy
Roche’s Tecentriq is a cancer immunotherapy that has the potential to be used in combination with other immunotherapies, targeted medicines and various chemotherapies across a broad range of cancers. ... In June this year, Tecentriq was approved by the
Subcutaneously administering Tecentriq reduced the time needed for treatment compared to standard IV infusion. ... The investigational subcutaneous formulation combines Tecentriq with Halozyme Therapeutics’ Enhanze drug delivery technology.
More from news
Approximately 75 fully matching, plus 91 partially matching documents found.
2019. The only drug that has any realistic chance of challenging Keytruda in NSCLC is Roche’s Tecentriq. ... The Tecentriq chemo trial, IMpower132, is the most important head-to-head with Keytruda (in non-squamous NSCLC).
The therapy area is dominated by Merck’s Keytruda, BMS’ Opdivo and Roche’s Tecentriq, but Pfizer is hoping that combinations such as its own Inlyta and Bavencio can help it
It’s not all been plain sailing, with BMS’ Opdivo (nivolumab) and Roche’s Tecentriq not doing as well as hoped in frontline NSCLC, revealing there are differences between checkpoint inhibitors – ... The drugmaker thinks Avastin may enhance
Tecentriq (for the treatment of urothelial carcinoma, only approved in the US), and Venclexta (for the treatment of chronic lymphocytic leukaemia, approved in the EU and US).
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
No results were found
A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...